MyMD Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
QCLS$0.35-6.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| For the Years Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Cash flows from operating activities: | ||||
| Net loss from ongoing operations | $(3,999,950) | $(15,197,336) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Gain (loss) on sale of marketable securities | (416) | 5,964 | ||
| Change in fair value of marketable securities | (514) | (2,958) | ||
| Change in fair value of derivatives | (3,088,800) | - | ||
| Change in fair value of warrants | (9,756,000) | - | ||
| Stock based compensation: | ||||
| Options issued to directors | 944,834 | - | ||
| Options issued to key employees | 1,962,138 | 338,922 | ||
| Options issued to non-employees | 142,565 | 105,420 | ||
| Warrants issued for services | - | 84,851 | ||
| Restricted stock units to non-employees | - | 165,997 | ||
| Change in assets and liabilities | ||||
| Prepaid expenses | (327,439) | 540,560 | ||
| Trade and other payables | 1,042,997 | 1,686,595 | ||
| Operating leases | (578) | 1,917 | ||
| Deferred compensation payable | 100,538 | - | ||
| Net cash used by operating activities | (12,980,625) | (12,270,068) | ||
| Cash flows from investing activities: | ||||
| Purchases of marketable securities | (13,454,304) | (4,836,837) | ||
| Proceeds from sale of marketable securities | 15,300,030 | 11,750,000 | ||
| Net cash provided by investing activities | 1,845,726 | 6,913,163 | ||
| Cash flows from financing activities | ||||
| Redemption of Series F Convertible Preferred Stock | (89,635) | - | ||
| Dividends on Series F Convertible Preferred Stock | (1,452,145) | - | ||
| Premium on Series F Convertible Preferred Stock | (77,090) | - | ||
| Net proceeds from the issuance of preferred stock | 14,685,689 | - | ||
| Net proceeds from issuance of common stock | - | 5,550,028 | ||
| Net cash provided by financing activities | 13,066,819 | 5,550,028 | ||
| Net increase in cash and cash equivalents | 1,931,920 | 193,123 | ||
| Cash and cash equivalents at beginning of year | 749,090 | 555,967 | ||
| Cash and cash equivalents at end of year | $2,681,010 | $749,090 | ||
| Supplemental cash flow information | ||||
| Cash paid for: | ||||
| Interest | $ | - | $13,322 | |
| Income Taxes | $ | - | $ | - |
| Supplemental Schedule of Non-Cash Financing and Investing Activities | ||||
| Operating lease right-of-use asset obtained in exchange for lease obligation | $ | - | $53,196 | |
| Initial fair value of warrant liabilities pursuant to the issuance of Series F Convertible Preferred Stock and Warrants | $10,623,000 | $ | - | |
| Initial fair value of derivative liabilities pursuant to the issuance of Series F Convertible Preferred Stock and Warrants | $3,149,800 | $ | - | |
The accompanying notes are an integral part to these consolidated financial statements.
MYMD PHARMACEUTICALS, INC. AND SUBSIDIARIES
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.